ArticleBioinformatics advances2025
bloodAGENT: a versatile tool for blood group typing and genomic variation analysis.
Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Accurate blood group allele determination is essential for both research and clinical applications. While next-generation sequencing and third-generation sequencing technologies provide a wealth of genomic data, secondary analysis pipelines often struggle with detecting variations in paralogous regions and maintaining haplotype integrity. Existing tools for blood group allele determination are frequently proprietary and lack the flexibility needed to address these challenges. To bridge this gap, we developed bloodAGENT, a versatile and open-source tool designed for analyzing genomic variation and resolving blood group alleles. Results: bloodAGENT achieves high concordance in blood group allele determination under typical conditions but reveals a strong dependence on data completeness. Simulations show that dropout rates are the primary determinant of concordance and ambiguities, with noticeable declines at dropout rates as low as 5%. While phasing breaks have a minor overall impact, their importance remains evident in specific scenarios. These results highlight bloodAGENT's robustness and its potential for handling complex genomic analyses. Availability and implementation: https://github.com/ikmb/bloodAGENT.git.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.